Amoéba, a French greentech specializing in the development of natural microbiological solutions, has announced the publication in the special issue of " Skin Anti-Aging Strategies "A scientific article on Willaertia lysate was published in the journal Cosmetics (MDPI group).
This article presents, for the first time to the international scientific community, the efficacy of Willaertia lysate on healing, pigmentation, as well as markers of intrinsic age-related aging and extrinsic aging caused by UV exposure. A patent has been filed to protect this innovation.
Amoéba reports that scientific data show a stimulation of specific genes associated with ageing, as well as an increase in the synthesis of skin markers such as collagen and hyaluronic acid in the dermis, epidermis and dermal-epidermal junction. We also observed an acceleration of wound healing by stimulating cell renewal, as well as regulation of skin pigmentation by reducing tyrosine kinase activity and melanin content. A reduction in markers of oxidative stress, one of the main causes of skin ageing, is also one of the notable results highlighted by Amoéba. These data were mainly obtained in tests carried out by independent specialized laboratories.
The results indicate that Willaertia lysate, a naturally-occurring postbiotic initially isolated from the hydrobiome of the Aix-les-Bains thermal waters, helps to improve healing, reduce pigmentation and attenuate the damaging effects of oxidative stress and the signs of skin aging. All these properties are in line with the current trend in the cosmetics market towards "ageing well" and longevity using natural, non-invasive methods.
"This first scientific paper in the field of cosmetics, on the efficacy of our Willaertia lysate against several signs of aging, is recognition on an international scale. These results were presented at the 15th "Skin Ageing & Challenges" conference on November 6, 2024. The data collected confirms the strong potential of Willaertia lysate as a cosmetic ingredient. We have also carried out a clinical test to confirm these results, which will be the subject of a future scientific publication."says Sandrine Troussieux, Amoéba's Scientific Director.
Founded in 2010, Amoéba is based in Chassieu, near Lyon. The company's ambition is to become a major player in the treatment of microbiological risk in the plant protection and cosmetics sectors.
